Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Yes, an MRI nomogram that combines habitat radiomics and clinical factors can predict high-risk LARC more accurately than single-feature models, helping guide treatment decisions.
Yes, photobiomodulation significantly reduces the risk of severe oral mucositis in head and neck cancer patients, with a 54% risk reduction shown in a recent meta-analysis.
About 48% of breast cancer patients experience chemotherapy-induced nausea and vomiting, with higher risk in younger patients and those with motion sickness history.
Yes, zinc supplements may help prevent oral mucositis after chemoradiotherapy, especially when started early and used topically, but evidence is limited.
For high-risk NMIBC, BCG plus mitomycin does not improve disease-free survival compared to BCG alone, and may increase toxicity.
Intravesical gemcitabine/docetaxel may offer similar or better recurrence-free survival with fewer side effects compared to BCG for non-muscle invasive bladder cancer, but…
Blood tests for oral cancer are not yet accurate enough for routine screening; recent research shows promising but variable results, with some methods achieving ~95% accuracy in…
Based on a meta-analysis of 17 studies, the average chance of delirium in advanced cancer is about 36% (roughly 1 in 3 patients).
Yes, a nomogram can predict moderate-to-severe complications after primary tumor resection in metastatic colorectal cancer, using factors like age and tumor size.
A 2025 systematic review found new standards for bladder cancer: perioperative durvalumab, enfortumab vedotin plus pembrolizumab, and HER2-targeted disitamab vedotin plus…
Yes, adjuvant pembrolizumab benefits selected high-risk RCC patients after surgery, improving disease-free and overall survival based on the KEYNOTE-564 trial.
Yes, blood test scores like COP-MPV, mGPS, NLR, and PLR are linked to survival in OSCC, but they are not precise enough to predict individual survival time.
New immunotherapy options for triple-negative breast cancer include immune checkpoint inhibitors like pembrolizumab combined with chemotherapy, which improve survival in…
Antibodies to Epstein-Barr virus (EBV) proteins, especially EBNA1, and circulating EBV DNA are linked to higher NPC risk.
No, intravenous vitamin C did not reduce stomach problems during chemotherapy for nasopharyngeal carcinoma in a clinical trial.
MicroRNAs are small RNA molecules that can promote or suppress melanoma growth, invasion, and spread by controlling gene activity and influencing the tumor's immune environment.
Yes, processed meat increases cancer risk for everyone, including people with cardiovascular diseases, due to shared risk factors and inflammatory pathways.
Yes, AI and digital pathology show promise for improving endometrial cancer diagnosis by analyzing tissue images and molecular data, but they are not yet standard practice.
NK cell immunotherapy for solid tumors faces major hurdles: poor tumor infiltration, the immunosuppressive tumor microenvironment, antigen heterogeneity, and limited persistence…
Yes, frailty significantly increases the likelihood of depression in adults with cancer, with frail patients having nearly six times higher odds of depressive symptoms.
Yes, a meta-analysis found that new lesions after lutetium-177 treatment are linked to worse overall survival in mCRPC patients.
Yes, a mindfulness intervention (MORE) is feasible for managing chronic pain in cancer survivors, based on a pilot RCT showing good enrollment, adherence, and satisfaction.
Yes, a 2025 survey found 94% of cancer patients are willing to try acupuncture, mainly for sleep, pain, and fatigue relief.
Olaparib plus bevacizumab is most effective in HRD-positive ovarian cancer; in HR-proficient tumors, benefit is limited, and resistance, side effects, and cost are key limitations.
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.